Paradigm Biopharmaceuticals Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm PPS nasal spray to treat Allergic Rhinitis
- Shareholders Update
- ASX Admission Market Release
- Paradigm Secures Key US Patent
- Paradigm Biopharmaceuticals Receives Ethics Approval
Later from Paradigm Biopharmaceuticals
- Paradigm PPS a potential in the treatment of viral arthritis
- Preclinical study underpins efficacy of Paradigms RhinosulR
- Paradigms Placement heavily oversubscribed
- Appendix 4C - September 2016 quarter
- Paradigms hay fever clinical trial cleared to commence
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals